Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) has been assigned a consensus rating of “Hold” from the fourteen ratings firms that are presently covering the firm, Marketbeat.com reports. Three research analysts have rated the stock with a sell rating, seven have given a hold rating and four have issued a buy rating on the company. The average 12 month price objective among brokers that have updated their coverage on the stock in the last year is $17.56.
IRWD has been the subject of several analyst reports. Credit Suisse Group initiated coverage on Ironwood Pharmaceuticals in a report on Monday, November 27th. They issued a “buy” rating and a $19.00 target price for the company. Zacks Investment Research upgraded Ironwood Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Thursday, January 18th. Morgan Stanley restated a “hold” rating on shares of Ironwood Pharmaceuticals in a report on Monday, December 4th. ValuEngine upgraded Ironwood Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Wednesday, November 29th. Finally, BidaskClub lowered Ironwood Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Thursday, December 7th.
Shares of Ironwood Pharmaceuticals (NASDAQ IRWD) opened at $13.67 on Friday. Ironwood Pharmaceuticals has a 1-year low of $12.89 and a 1-year high of $19.94. The company has a quick ratio of 4.86, a current ratio of 4.87 and a debt-to-equity ratio of -22.31. The firm has a market capitalization of $2,050.00, a P/E ratio of -14.24 and a beta of 1.28.
A number of hedge funds and other institutional investors have recently modified their holdings of IRWD. Zurcher Kantonalbank Zurich Cantonalbank increased its position in Ironwood Pharmaceuticals by 128.6% in the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 9,010 shares of the biotechnology company’s stock worth $135,000 after buying an additional 5,069 shares during the period. Gerber Kawasaki Wealth & Investment Management bought a new stake in shares of Ironwood Pharmaceuticals during the third quarter valued at approximately $170,000. Hemenway Trust Co LLC bought a new stake in shares of Ironwood Pharmaceuticals during the fourth quarter valued at approximately $204,000. Ameritas Investment Partners Inc. increased its position in shares of Ironwood Pharmaceuticals by 5.8% during the second quarter. Ameritas Investment Partners Inc. now owns 11,821 shares of the biotechnology company’s stock valued at $223,000 after purchasing an additional 648 shares during the period. Finally, Virtu KCG Holdings LLC increased its position in shares of Ironwood Pharmaceuticals by 10.3% during the second quarter. Virtu KCG Holdings LLC now owns 15,740 shares of the biotechnology company’s stock valued at $297,000 after purchasing an additional 1,470 shares during the period.
Ironwood Pharmaceuticals Company Profile
Ironwood Pharmaceuticals, Inc is a biotechnology company. The Company is advancing product opportunities in areas of unmet need, including irritable bowel syndrome with constipation (IBS C), and chronic idiopathic constipation (CIC), hyperuricemia associated with uncontrolled gout, uncontrolled gastroesophageal reflux disease (uncontrolled GERD), and vascular and fibrotic diseases.
Receive News & Ratings for Ironwood Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ironwood Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.